The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

被引：10
作者：
Lunning, Matthew A. [1 ]
Migliacci, Jocelyn C. [2 ]
Hilden, Patrick [3 ]
Devlin, Sean M. [3 ]
Castro-Malaspina, Hugo [2 ,4 ]
Giralt, Sergio [2 ,4 ]
Perales, Miguel-Angel [2 ,4 ]
Zelenetz, Andrew D. [2 ,4 ]
Moskowitz, Craig H. [2 ,4 ]
Sauter, Craig S. [2 ,4 ]
机构：
[1] Univ Nebraska, Dept Med, Omaha, NE USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[4] Weill Cornell Med Coll, Dept Med, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷 / 02期
关键词：
follicular lymphoma; stem cell transplantation; non-Hodgkin lymphoma; STEM-CELL TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; RESPONSE CRITERIA; FREE SURVIVAL; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; DOXORUBICIN; IMPROVES; THERAPY;
D O I：
10.1111/bjh.13947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Early relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post-rituximab era. No difference in event-free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of <= 12 months (80% and 42% at 3years, P < 0015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.
引用
收藏
页码：260 / 264
页数：5
相关论文
共 15 条
  • [1] Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Avivi, Irit
    Montoto, Silvia
    Canals, Carme
    Maertens, John
    Al-Ali, Haifa
    Mufti, Ghulam J.
    Finke, Juergen
    Schattenberg, Anton
    Fanin, Renato
    Cornelissen, Jan J.
    Vernant, Jean-Paul
    Russell, Nigell
    Beguin, Yves
    Thomson, Kirsty
    Verdonck, Leo F.
    Kobbe, Guido
    Tilly, Herve
    Socie, Gerard
    Sureda, Anna
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (05) : 719 - 728
  • [2] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
    Casulo, Carla
    Byrtek, Michelle
    Dawson, Keith L.
    Zhou, Xiaolei
    Farber, Charles M.
    Flowers, Christopher R.
    Hainsworth, John D.
    Maurer, Matthew J.
    Cerhan, James R.
    Link, Brian K.
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) : 2516 - U55
  • [3] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [4] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [5] Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab
    Evens, Andrew M.
    Vanderplas, Ann
    LaCasce, Ann S.
    Crosby, Allison L.
    Nademanee, Auayporn P.
    Kaminski, Mark S.
    Abel, Gregory A.
    Millenson, Michael
    Czuczman, Myron S.
    Rodriguez, Maria A.
    Niland, Joyce
    Zelenetz, Andrew D.
    Gordon, Leo I.
    Friedberg, Jonathan W.
    [J]. CANCER, 2013, 119 (20) : 3662 - 3671
  • [6] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    [J]. BLOOD, 2005, 106 (12) : 3725 - 3732
  • [7] Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Khouri, Issa F.
    McLaughlin, Peter
    Saliba, Rima M.
    Hosing, Chitra
    Korbling, Martin
    Lee, Ming S.
    Medeiros, L. Jeffrey
    Fayad, Luis
    Samaniego, Felipe
    Alousi, Amin
    Anderlini, Paolo
    Couriel, Daniel
    de Lima, Marcos
    Giralt, Sergio
    Neelapu, Sattva S.
    Ueno, Naoto T.
    Samuels, Barry I.
    Hagemeister, Fredrick
    Kwak, Larry W.
    Champlin, Richard E.
    [J]. BLOOD, 2008, 111 (12) : 5530 - 5536
  • [8] Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
    Klyuchnikov, Evgeny
    Bacher, Ulrike
    Kroeger, Nicolaus M.
    Hari, Parameswaran N.
    Ahn, Kwang Woo
    Carreras, Jeanette
    Bachanova, Veronika
    Bashey, Asad
    Cohen, Jonathon B.
    D'Souza, Anita
    Freytes, Cesar O.
    Gale, Robert Peter
    Ganguly, Siddhartha
    Hertzberg, Mark S.
    Holmberg, Leona A.
    Kharfan-Dabaja, Mohamed A.
    Klein, Andreas
    Ku, Grace H.
    Laport, Ginna G.
    Lazarus, Hillard M.
    Miller, Alan M.
    Mussetti, Alberto
    Olsson, Richard F.
    Slavin, Shimon
    Usmani, Saad Z.
    Vij, Ravi
    Wood, William A.
    Maloney, David G.
    Sureda, Anna M.
    Smith, Sonali M.
    Hamadani, Mehdi
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (12) : 2091 - 2099
  • [9] Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
    Kornacker, M.
    Stumm, J.
    Pott, C.
    Dietrich, S.
    Suessmilch, S.
    Hensel, M.
    Nickelsen, M.
    Witzens-Harig, M.
    Kneba, M.
    Schmitz, N.
    Ho, A. D.
    Dreger, P.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (04) : 722 - 728
  • [10] Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma
    Reddy, N.
    Greer, J. P.
    Goodman, S.
    Engelhardt, B.
    Oluwole, O.
    Jagasia, M. H.
    Savani, B. N.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 (10) : 1318 - 1320
12